A5062848476- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
- Endometrial and Cervical Cancer Treatments
- Pneumonia and Respiratory Infections
- Monoclonal and Polyclonal Antibodies Research
- Multiple and Secondary Primary Cancers
- Cancer Immunotherapy and Biomarkers
- Respiratory and Cough-Related Research
- Circular RNAs in diseases
- Antibiotics Pharmacokinetics and Efficacy
- Estrogen and related hormone effects
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Advances in Oncology and Radiotherapy
- Food Allergy and Anaphylaxis Research
- Cancer, Stress, Anesthesia, and Immune Response
- Nanoplatforms for cancer theranostics
- Contact Dermatitis and Allergies
- Neutropenia and Cancer Infections
- Blood Coagulation and Thrombosis Mechanisms
Northwell Health
2019-2024
IJ Research (United States)
2021-2024
Cancer Institute (WIA)
2023
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
2021-2022
North Shore Diabetes and Endocrine Associates
2022
Hofstra University
2012-2021
North Shore University Hospital
2009-2020
New York University
2009
Bassett Healthcare Network
1997-1998
The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus (TH) and yielded clinically acceptable invasive disease-free survival (iDFS) among patients stage I human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).Patients centrally confirmed HER2+ BC were randomly assigned 3:1 T-DM1 or TH received 3.6 mg/kg IV every 3 weeks for 17 cycles T 80 mg/m2 H once week × 12 (4 load →2 mg/kg), followed by...
Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need.
Abstract Background: The APT trial previously demonstrated that adjuvant TH is associated with favorable outcomes in patients (pts) small HER2-positive BC. ATEMPT sought to determine if T-DM1 less toxicity than TH, and it a clinically acceptable disease-free-survival (DFS) pts Stage I HER2+ Methods: an investigator-initiated, randomized, multicenter, phase II study of vs TH. Pts centrally confirmed BC (IHC 3 + and/or FISH > 2.0) were eligible. randomized 3:1 or received 3.6 mg/kg IV...
ABSTRACT To investigate whether grapefruit juice inhibits the metabolism of clarithromycin, 12 healthy subjects were given water or before and after a clarithromycin dose 500 mg in randomized crossover study. Administration increased time to peak concentration both (82 ± 35 versus 148 83 min; P = 0.02) 14-hydroxyclarithromycin (84 38 min 173 85; 0.01) but did not affect other pharmacokinetic parameters.
Abstract The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1) the ATEMPT trial and favorable toxicity profile associated this agent make T-DM1 a potential therapeutic option for select stage I HER2-positive breast cancer. Moreover, is an established treatment cancer residual invasive disease after neoadjuvant therapy. Given that cardiotoxicity most significant adverse event of trastuzumab, which main molecular component T-DM1, we conducted sub-analysis...
Cyclin-dependent kinase 4/6 inhibitors have become part of the standard care in treatment hormone receptor positive, Her2Neu negative metastatic breast cancer. There is concern regarding efficacy and potential increased cyclin-dependent toxicity geriatric population community compared to clinical trial population.We evaluated patients treated with from 2015 2019 stratified according age ≥70 <70 years. Complete blood count first two cycles was recorded. Rates hematologic toxicities, dose...
e12615 Background: The KEYNOTE-522 trial showed a significant improvement in pathological complete response (pCR) and event-free survival (EFS), leading to the FDA approval of pembrolizumab (pembro) combined with NACT for high-risk, early-stage TNBC. However, it utilized q3-week dosing doxorubicin + cyclophosphamide (AC), not ddAC regimen, which superior overall (OS) CALGB 9741 EBCTCG trials. Consequently, superiority regimen over remains uncertain. This retrospective case-control study...
Abstract Background: CRA is a surrogate for ovarian toxicity and associated risk of infertility long-term menopausal symptoms. Therefore, it important to assess report the rate when we study new neoadjuvant treatment regimen. In Adjuvant Paclitaxel Tratuzumab (APT) trial, found that with adjuvant TH (12 weeks paclitaxel year trastuzumab) human epidermal growth factor receptor-2 (HER2)-positive breast cancer was lower than historically seen cyclophosphamide-based regimens. The ATEMPT trial...
Abstract Background: The ATEMPT trial primary analysis found that one year of adjuvant trastuzumab emtansine (T-DM1) achieved a 3-year iDFS 97.8% for patients with stage I HER2+ breast cancer, but was not associated fewer clinically relevant toxicities (CRTs) compared paclitaxel and (TH). In this end-of-study analysis, we report 5-year survival outcomes correlative analyses from the trial. Methods: Patients centrally confirmed cancer were randomly assigned 3:1 to T-DM1 or TH received 3.6...
ABSTRACT The present study was conducted to identify any potential interaction between oral cimetidine and clarithromycin. Twelve healthy subjects were administered single doses of clarithromycin alone with dosed steady state. Cimetidine prolonged the absorption clarithromycin, as evidenced by decreased peak concentrations both 14-OH-clarithromycin (14OHC) in serum (46 43%, respectively), a delay formation 14OHC (increase 68%), increases their half-lives (75 82%, despite no changes total...
Although paradoxic excitation may rarely occur in children and adults with conventional dosages of antihistamines, few case reports have appeared the literature. We cared for a 46-year-old patient who became extremely agitated after receiving dose intravenous diphenhydramine.
Abstract Purpose: The ATEMPT trial sought to determine if adjuvant T-DM1 (every 3 wks for 1 yr) Stage I HER2 positive breast cancer is better tolerated than TH (paclitaxel weekly x 12 with yr of trastuzumab). Here we compare patient-reported outcomes (PROs) including quality life (QOL), specific symptoms, and work productivity between the two treatments over time. Patients Methods: English-speaking patients were randomized (3:1) or TH, completed PRO assessments at baseline (day 1), wks, 6,...
Introduction: Over the last few years, targeted therapy has become mainstay maintenance treatment of patients with ovarian cancer including BRCA1/BRCA2 mutations. Poly ADP ribose polymerase inhibitors (PARPi) are effective in who complete or partial remission. PARPi known to cause hematological adverse events (AEs), but have not been compared directly each other. Objective: Primary objective was compare incidence and non-hematological AEs associated use PARPi. Methods: This a single...
Benefits and limitations in using NCCN guidelines to distinguish TP53 CH from mosaic LFS.
e16546 Background: Carboplatin sensitivity in drug resistance assays has been shown to be an independent predictor of longer progression free interval with conflicting results overall survival. We evaluated vitro for carboplatin and paclitaxel combination its correlation survival (PFS) (OS). Methods: From April 1, 2006 December 12, 2011, were sent after cytoreductive surgery primary epithelial ovarian cancer. Patients analyzed according scoring system low (S), intermediate (I), extreme (R)....
e17555 Background: Over the last few years, targeted therapy has become mainstay maintenance treatment of patients with ovarian cancer including BRCA1 or BRCA2 mutations. Poly ADP ribose polymerase (PARP) inhibitors are effective in who complete partial remission. PARP known to cause hematological adverse events (AEs), but have not been compared directly each other. Methods: We conducted a single institution, IRB approved, retrospective study on were treated from December 2016 October 2020....
e17627 Background: The landscape for the treatment of microsatellite-stable-recurrent endometrial cancer has changed with published results KEYNOTE-775, demonstrating an overall response rate 37.2% Pembrolizumab and Lenvatinib 20 mg. However, recent retrospective studies have suggested that a lower dose may be safer equally efficacious. We aimed to retrospectively review our institutional data compare efficacy toxicity at low (≤10 mg) vs. high (>10 dose. Methods: Retrospective patients...
Abstract Background: Epithelial ovarian cancer accounts for 90% of all cases malignant tumors the ovaries, majority patients are diagnosed at stage III disease with 70% them succumbing to their within 5 years. Objectives: We addressed 3 questions 1) there patterns in pre-surgical miRNA profiles between survivors and who do not survive “surviving pattern” (SP) 2) changes that occur during or after chemotherapy convert into SP. 3) Do benign masses have SP? Methods: Between 2004 2011 we...
1046 Background: Breast cancer is by far more common in W than B women. Black women have aggressive disease that occurs almost a decade earlier, it usually triple negative and has lower survival. Objectives to determine 1) if plasma miRNA expression differs between women, 2) variation miRs may explain the observed survival difference TNBC compared Methods: We determined profiles collected before removal of breast tumors three groups women: normal controls (N), TN ER/PR positive BC....
e17058 Background: Dose-dense chemotherapy is increasingly more utilized in the adjuvant treatment of patients (pts) with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), as compared to conventional q3 week regimen. The safety and tolerability dose-dense regimen pts ≥65 yrs old has not been well studied. We performed a retrospective analysis stage II-IV EOC treated at our institution either Methods: identified Northwell Health from 2010-2015 who received...